CONFIDENTIAL PORTIONS OMITTED PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934 Patent License Agreement between the University of Alberta and Cortex Pharmaceuticals, Inc. Use of AMPAKINE® compounds to Treat Respiratory DepressionPatent License Agreement • March 17th, 2008 • Cortex Pharmaceuticals Inc/De/ • Pharmaceutical preparations • Delaware
THIS AGREEMENT, dated as of May 9, 2007 (the “Signature Date”), between Cortex Pharmaceuticals, Inc., having its principal offices at 15241 Barranca Parkway, Irvine, California (“Cortex”), and The Governors of the University of Alberta, located at Suite 4000, 8308-114 Street, Edmonton, Alberta, Canada (the “University”). Cortex Pharmaceuticals, Inc. and The Governors of the University of Alberta may each be referred to herein individually as a “Party” and collectively as the “Parties”.
